{"id":"switch-to-dtg-3tc","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL6068498","moleculeType":"Vaccine component"},"_fixedAt":"2026-03-30T13:11:58.753467","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the enzyme responsible for inserting HIV DNA into human chromosomes, preventing viral replication at a critical step. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that terminates HIV RNA-dependent DNA synthesis. Together, this dual-agent combination provides potent antiretroviral activity with a high genetic barrier to resistance.","oneSentence":"DTG (dolutegravir) inhibits HIV integrase to prevent viral DNA integration into the host genome, while 3TC (lamivudine) inhibits reverse transcriptase to block HIV replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:16.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced or treatment-naive adults"},{"name":"HIV-1 infection as part of combination antiretroviral therapy"}]},"_fixedFields":["pubmed(93)"],"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT05373758","phase":"NA","title":"A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-02-07","conditions":"HIV Infections, AIDS, Virologic Failure","enrollment":648},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT05393193","phase":"PHASE4","title":"POC HIV Testing and Early DTG Use for Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2022-07-04","conditions":"HIV","enrollment":900},{"nctId":"NCT05911360","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-01-31","conditions":"HIV, HIV Infections","enrollment":205},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT06967753","phase":"PHASE4","title":"Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)","status":"RECRUITING","sponsor":"UBATEC","startDate":"2025-07-31","conditions":"HIV, HIV-1","enrollment":50},{"nctId":"NCT06444620","phase":"PHASE3","title":"B/F/TAF to DTG/3TC Switch Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nairobi","startDate":"2024-07-22","conditions":"HIV-1-infection","enrollment":240},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT04034862","phase":"PHASE3","title":"Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs","status":"COMPLETED","sponsor":"University of Liege","startDate":"2019-10-01","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04019873","phase":"","title":"'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-18","conditions":"HIV Infections","enrollment":774},{"nctId":"NCT05477407","phase":"NA","title":"Adipose Tissue After Switch to Doravirine","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2022-10-06","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT05289986","phase":"PHASE4","title":"The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-11-21","conditions":"Hiv","enrollment":18},{"nctId":"NCT04585737","phase":"PHASE4","title":"Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF","status":"COMPLETED","sponsor":"Charlotte-Paige Rolle, MD","startDate":"2020-10-05","conditions":"HIV I Infection","enrollment":222},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT06602622","phase":"PHASE4","title":"Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2024-08-14","conditions":"HIV, HIV Associate Weight Loss, HIV-1 Infection","enrollment":108},{"nctId":"NCT06580873","phase":"PHASE4","title":"Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)","status":"NOT_YET_RECRUITING","sponsor":"Saskatchewan Health Authority - Regina Area","startDate":"2024-09-30","conditions":"HIV-1-infection, Opioid Use Disorder","enrollment":40},{"nctId":"NCT04904406","phase":"PHASE4","title":"Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals","status":"COMPLETED","sponsor":"Thomas Benfield","startDate":"2020-10-22","conditions":"Hiv, HIV Infections, HIV Cardiomyopathy","enrollment":81},{"nctId":"NCT04553081","phase":"PHASE4","title":"2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-05-26","conditions":"HIV-1-infection","enrollment":134},{"nctId":"NCT04021290","phase":"PHASE3","title":"Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-11","conditions":"HIV Infections","enrollment":493},{"nctId":"NCT04826562","phase":"PHASE4","title":"Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)","status":"UNKNOWN","sponsor":"Saint Michael's Medical Center","startDate":"2021-09-26","conditions":"Human Immunodeficiency Virus","enrollment":40},{"nctId":"NCT04050449","phase":"","title":"Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-10-28","conditions":"HIV-1-infection","enrollment":1339},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT03446573","phase":"PHASE3","title":"Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-01-18","conditions":"HIV Infections","enrollment":743},{"nctId":"NCT05493969","phase":"PHASE4","title":"Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Public Health Clinical Center","startDate":"2022-08","conditions":"Acquired Immunodeficiency Syndrome","enrollment":100},{"nctId":"NCT03685500","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-12-04","conditions":"HIV Infections","enrollment":78},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03447873","phase":"PHASE4","title":"Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2017-06-01","conditions":"HIV Infections","enrollment":153},{"nctId":"NCT04979468","phase":"PHASE3","title":"Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)","status":"UNKNOWN","sponsor":"Societa' Italiana Di Malattie Infettive E Tropicali","startDate":"2021-03-23","conditions":"HIV-1-infection","enrollment":440},{"nctId":"NCT04903847","phase":"PHASE4","title":"Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil","status":"UNKNOWN","sponsor":"Thomas Benfield","startDate":"2021-02-02","conditions":"Hiv, HIV Infections, HIV Lipodystrophy","enrollment":126},{"nctId":"NCT03549689","phase":"PHASE2","title":"Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)","status":"WITHDRAWN","sponsor":"Philip Grant","startDate":"2019-08-01","conditions":"HIV/AIDS, HIV-1-infection, Osteopenia","enrollment":""},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT03067285","phase":"PHASE4","title":"A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-09-08","conditions":"HIV Infections","enrollment":39},{"nctId":"NCT04155554","phase":"PHASE3","title":"Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Senese","startDate":"2020-01-29","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02509195","phase":"PHASE4","title":"SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08-04","conditions":"HIV","enrollment":40},{"nctId":"NCT03275701","phase":"NA","title":"Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC","status":"UNKNOWN","sponsor":"Mills Clinical Research","startDate":"2016-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":50},{"nctId":"NCT02105987","phase":"PHASE3","title":"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04","conditions":"Infection, Human Immunodeficiency Virus","enrollment":555},{"nctId":"NCT02067767","phase":"PHASE2","title":"Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2014-02","conditions":"HIV-1 Infection","enrollment":53},{"nctId":"NCT01966822","phase":"PHASE3","title":"Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2014-01","conditions":"HIV-1 Infection","enrollment":75},{"nctId":"NCT02285374","phase":"PHASE4","title":"Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2014-11","conditions":"HIV","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":93,"recentPublications":[{"date":"2026 Mar 7","pmid":"41795213","title":"Real-world use of second-generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS-CO3-AquiVIH-NA cohort.","journal":"HIV medicine"},{"date":"2026 Mar","pmid":"41755425","title":"Comparative effectiveness of dolutegravir + lamivudine versus three-drug regimens in Swedish clinical practice: a nationwide study.","journal":"Journal of the International AIDS Society"},{"date":"2026 Feb 26","pmid":"41746122","title":"Antiretroviral therapy switch among Medicare beneficiaries with HIV.","journal":"Journal of managed care & specialty pharmacy"},{"date":"2026 Feb 23","pmid":"41729047","title":"Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort.","journal":"AIDS (London, England)"},{"date":"2026 Feb","pmid":"41706288","title":"Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States.","journal":"Drugs & aging"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Switch to DTG + 3TC","genericName":"Switch to DTG + 3TC","companyName":"Hospitales Universitarios Virgen del Rocío","companyId":"hospitales-universitarios-virgen-del-roc-o","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DTG (dolutegravir) inhibits HIV integrase to prevent viral DNA integration into the host genome, while 3TC (lamivudine) inhibits reverse transcriptase to block HIV replication. Used for HIV-1 infection in treatment-experienced or treatment-naive adults, HIV-1 infection as part of combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}